MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:41Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:TNF inhibitors]]
			[[Category:Biologics]]
			[[Category:DMARDs]]
			[[Category:Immunosuppressants]]
			[[Category:Monoclonal antibodies]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #144

2026-05-23T04:15:05Z

parser-claude batch MedTemplate pre-fill, Top 300 #144

New page

{{MedTemplate
| generic = Adalimumab
| brand = Humira; biosimilars Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Yusimry, Abrilada
| structure =
| classes = [[:Category:TNF_inhibitors|TNF-α inhibitor]], [[:Category:Biologics|Biologic]], [[:Category:DMARDs|DMARD]], [[:Category:Immunosuppressants|Immunosuppressant]], [[:Category:Monoclonal_antibodies|Monoclonal antibody (fully human IgG1)]]
| uses = <vote slug="rheumatoid-arthritis-use">Rheumatoid arthritis</vote>, <vote slug="psoriatic-arthritis-use">Psoriatic arthritis</vote>, <vote slug="ankylosing-spondylitis-use">Ankylosing spondylitis</vote>, <vote slug="crohn-use">Crohn's disease</vote>, <vote slug="ulcerative-colitis-use">Ulcerative colitis</vote>, <vote slug="plaque-psoriasis-use">Moderate-to-severe plaque psoriasis</vote>, <vote slug="hidradenitis-suppurativa-use">Hidradenitis suppurativa</vote>, <vote slug="uveitis-noninfectious-use">Non-infectious uveitis</vote>, <vote slug="jia-use">Juvenile idiopathic arthritis</vote>
| starting_dose = 40 mg SC every other week (most adult indications); IBD induction 160 mg week 0, 80 mg week 2, then 40 mg every other week
| preparations = 40 mg/0.4 mL or 40 mg/0.8 mL prefilled syringe and autoinjector pen; 10, 20, 80 mg pediatric/induction strengths
| fda_max = 40 mg every week (selected indications); otherwise 40 mg every other week
| pill_id =
| routes = Subcutaneous
| onset = Symptomatic effect within weeks; full response by 12-24 weeks
| duration = 2 weeks per dose
| halflife = ~14 days<ref name="humira-label">FDA Prescribing Information, Humira (adalimumab), AbbVie, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125057s415lbl.pdf</ref>
| bioavailability = ~64% from SC depot<ref name="humira-label" />
| pregnancy = Generally continued through pregnancy when needed for disease control; placental transfer is minimal in the first trimester but increases in third trimester, so dose timing around delivery and considerations for live-vaccine schedule in the infant are standard.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US. Carries '''Boxed Warnings''' for serious infections (TB reactivation, invasive fungal, opportunistic bacterial/viral) and malignancy (lymphoma, including rare hepatosplenic T-cell lymphoma in young patients with IBD on combination immunosuppression)<ref name="humira-label" />
| mechanism = <vote slug="adalimumab-mech-claim">Adalimumab is a fully human recombinant IgG1 monoclonal antibody that binds tumor necrosis factor α (TNF-α), neutralizing its interaction with TNF receptors 1 and 2 and lysing TNF-α-expressing cells via Fc-mediated complement and ADCC; the net effect is broad suppression of TNF-driven inflammatory signaling in immune-mediated diseases.</vote> Pre-treatment screening for latent TB (PPD or IGRA) and chronic hepatitis B is standard. Anti-drug antibody formation is a recognized cause of secondary loss of response<ref name="humira-label" />.
}}

== References ==
<references />

Adalimumab - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #144